Davis Polk Advises InnoCare Pharma Limited on Its HK$2.24 Billion Initial Public Offering
March 25, 2020
March 25, 2020
NEW YORK, March 25 -- Davis Polk and Wardwell, a law firm, issued the following news:
Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HK$2.24 billion ($287 million) prior to any exercise of the over-allotment option.
InnoCare Pharma is a clinical stage . . .
Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A and Regulation S. The gross proceeds from the offering amounted to approximately HK$2.24 billion ($287 million) prior to any exercise of the over-allotment option.
InnoCare Pharma is a clinical stage . . .